Connection

Dongliang Yang to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Dongliang Yang has written about Antibodies, Monoclonal, Humanized.
Dongliang Yang
Connection Strength
0.012
Antibodies, Monoclonal, Humanized
  1. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Front Med. 2021 Jun; 15(3):486-494.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.